Pre-transplant immune state defined by serum markers and alloreactivity predicts acute rejection after living donor kidney transplantation

Clinical Transplantation

Volumn 28, Issue 9, 2014, Pages 968-979

  Vondran, Florian W R ^a   Timrott, Kai ^a   Kollrich, Sonja ^a   Steinhoff, Ann Kristin ^a   Kaltenborn, Alexander ^a,b   Schrem, Harald ^a   Klempnauer, Juergen ^a   Lehner, Frank ^a   Schwinzer, Reinhard ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Armed Forces Hospital Westerstede   (Germany)

Author keywords

Acute rejection; CD161; Kidney transplantation; sCD25; sCD30; sCD44

Indexed keywords

CD161 ANTIGEN; CD28 ANTIGEN; CD30 ANTIGEN; HERMES ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; BIOLOGICAL MARKER; CD44 PROTEIN, HUMAN; IL2RA PROTEIN, HUMAN;

ACUTE GRAFT REJECTION; ADULT; ALLOIMMUNITY; ANTIGEN DETECTION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVING DONOR; MALE; MIXED LYMPHOCYTE CULTURE; NATURAL KILLER CELL; PREOPERATIVE PERIOD; PROGNOSIS; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; BLOOD; FOLLOW UP; GRAFT REJECTION; IMMUNOLOGY; KIDNEY FAILURE, CHRONIC; LYMPHOCYTE ACTIVATION; MIDDLE AGED; POSTOPERATIVE CARE; PREDICTIVE VALUE; RISK FACTOR;

ADULT; ANTIGENS, CD30; ANTIGENS, CD44; BIOLOGICAL MARKERS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LIVING DONORS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; MALE; MIDDLE AGED; POSTOPERATIVE CARE; PREDICTIVE VALUE OF TESTS; RISK FACTORS;

EID: 84908370322     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12399     Document Type: Article

References (49)

1. Krieger NR, Becker BN, Heisey DM et al. Chronic allograft nephropathy uniformly affects recipients of cadaveric, nonidentical living-related, and living-unrelated grafts. Transplantation 2003: 75: 1677.
2. Li C, Yang CW. The pathogenesis and treatment of chronic allograft nephropathy. Nat Rev Nephrol 2009: 5: 513.
3. Opelz G, Dohler B. Effect of human leukocyte antigen compatibility on kidney graft survival: comparative analysis of two decades. Transplantation 2007: 84: 137.
4. Lee PC, Ozawa M. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation. Clin Transpl 2007: 219.
5. Vaidya S. Clinical importance of anti-human leukocyte antigen-specific antibody concentration in performing calculated panel reactive antibody and virtual crossmatches. Transplantation 2008: 85: 1046.
6. Vondran FW, Timrott K, Tross J et al. Association of high anti-donor alloreactivity and low frequency of FoxP3-expressing cells prior to kidney transplantation with acute graft rejection. Clin Transplant 2011: 25: 905.
7. Game DS, Lechler RI. Pathways of allorecognition: implications for transplantation tolerance. Transpl Immunol 2002: 10: 101.
8. Garcia-Roca P, Vargas YA, Fuentes Y et al. Serum soluble interleukin 2 receptor (sIL-2R) as a marker of acute rejection in renal transplant children. Pediatr Transplant 2012: 16: 274.
9. Kaden J, Schutze B, May G. A critical analysis of soluble interleukin-2 receptor levels in kidney allograft recipients. Transpl Int 1996: 9(Suppl. 1): S63.
10. Hamza A, Fischer K, Loertzer H, Fornara P. Is the determination of the soluble interleukin-2 receptor after application of interleukin-2 receptor antibodies still appropriate for immunological monitoring after renal transplantation? Urol Int 2006: 77: 232.
11. Panigrahi A, Deka R, Bhowmik D et al. Functional assessment of immune markers of graft rejection: a comprehensive study in live-related donor renal transplantation. Clin Transplant 2006: 20: 85.
12. Susal C, Pelzl S, Dohler B, Opelz G. Identification of highly responsive kidney transplant recipients using pretransplant soluble CD30. J Am Soc Nephrol 2002: 13: 1650.
13. Kamali K, Abbasi MA, Farokhi B et al. Posttransplant soluble CD30 as a predictor of acute renal allograft rejection. Exp Clin Transplant 2009: 7: 237.
14. Amirzargar MA, Amirzargar A, Basiri A et al. Early post-transplant immune monitoring can predict long-term kidney graft survival: soluble CD30 levels, anti-HLA antibodies and IgA-anti-Fab autoantibodies. Hum Immunol 2014: 75: 47.
15. Hirt-Minkowski P, Roth M, Honger G, Amico P, Hopfer H, Schaub S. Soluble CD30 correlates with clinical but not subclinical renal allograft rejection. Transpl Int 2013: 26: 75.
16. Susal C, Opelz G. Posttransplant sCD30 as a biomarker to predict kidney graft outcome. Clin Chim Acta 2012: 413: 1350.
17. Platt RE, Wu KS, Poole K, Newstead CG, Clark B. Soluble CD30 as a prognostic factor for outcome following renal transplantation. J Clin Pathol 2009: 62: 662.
18. Krettek A, Sukhova GK, Schonbeck U, Libby P. Enhanced expression of CD44 variants in human atheroma and abdominal aortic aneurysm: possible role for a feedback loop in endothelial cells. Am J Pathol 2004: 165: 1571.
19. Rouschop KM, Roelofs JJ, Rowshani AT et al. Pre-transplant plasma and cellular levels of CD44 correlate with acute renal allograft rejection. Nephrol Dial Transplant 2005: 20: 2248.
20. Rouschop KM, Roelofs JJ, Sylva M et al. Renal expression of CD44 correlates with acute renal allograft rejection. Kidney Int 2006: 70: 1127.
21. Solez K, Colvin RB, Racusen LC et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008: 8: 753.
22. Vondran FW, Timrott K, Kollrich S, Klempnauer J, Schwinzer R, Becker T. Decreased frequency of peripheral CD4(+) CD161(+) Th(17) -precursor cells in kidney transplant recipients on long-term therapy with belatacept. Transpl Int 2012: 25: 455.
23. Vondran FW, Timrott K, Tross J et al. Impact of basiliximab on regulatory T-cells early after kidney transplantation: down-regulation of CD25 by receptor modulation. Transpl Int 2010: 23: 514.
24. Meier-Kriesche HU, Ojo AO, Hanson JA et al. Increased impact of acute rejection on chronic allograft failure in recent era. Transplantation 2000: 70: 1098.
25. Tejani A, Ho PL, Emmett L, Stablein DM. Reduction in acute rejections decreases chronic rejection graft failure in children: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Am J Transplant 2002: 2: 142.
26. Harmon WE, Parkman R, Lavin PT et al. Comparison of cell-mediated lympholysis and mixed lymphocyte culture in the immunologic evaluation for renal transplantation. J Immunol 1982: 129: 1573.
27. Tanaka Y, Ohdan H, Onoe T et al. Low incidence of acute rejection after living-donor liver transplantation: immunologic analyses by mixed lymphocyte reaction using a carboxyfluorescein diacetate succinimidyl ester labeling technique. Transplantation 2005: 79: 1262.
28. van der Mast BJ, van Besouw NM, de Kuiper P et al. Pretransplant donor-specific helper T cell reactivity as a tool for tailoring the individual need for immunosuppression. Transplantation 2001: 72: 873.
29. Bohmig GA, Saemann MD, Bergmann M et al. Long-term evaluation of proliferative donor antigen-specific reactivity in cadaveric kidney transplant recipients. Transpl Int 2000: 13: 187.
30. Cochrum KC, Salvatierra O, Belzer FO. Correlation between MLC stimulation and graft survival in living related and cadaver transplants. Ann Surg 1974: 180: 617.
31. Creemers P, Du Toit E, Cassidy MJ, Kahn D. Sequential mixed lymphocyte culture after kidney transplantation: induction of tolerance or sensitization. Nephron 1997: 75: 166.
32. Velasquez SY, Garcia LF, Opelz G, Alvarez CM, Susal C. Release of soluble CD30 after allogeneic stimulation is mediated by memory T cells and regulated by IFN-gamma and IL-2. Transplantation 2013: 96: 154.
33. Pickeral JJ, Marcus RJ, Hsia S, Miller LL, Nghiem DD. Elevated soluble interleukin 2 receptor levels found among kidney transplant recipients. Transplantation 1997: 64: 1202.
34. Mehta R, Shah G, Adler W, Kittur D. Soluble interleukin 2 receptor (sIL-2R) levels in renal transplant recipients. Clin Transplant 2004: 18(Suppl. 12): 67.
35. Chen Y, Tai Q, Hong S et al. Pretransplantation soluble CD30 level as a predictor of acute rejection in kidney transplantation: a meta-analysis. Transplantation 2012: 94: 911.
36. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982: 143: 29.
37. Schrem H, Reichert M, Reichert B et al. Value of the SOFA score as a predictive model for short-term survival in high-risk liver transplant recipients with a pre-transplant labMELD score >/= 30. Langenbecks Arch Surg 2012: 397: 717.
38. Hosmer DWJ, Lemeshow S, Sturdivant RX. Applied Logistic Regression, 3rd edn. New York: John Wiley & Sons, 2013.
39. Jayaram D, Kommareddi M, Sung RS, Luan FL. Delayed graft function requiring more than one-time dialysis treatment is associated with inferior clinical outcomes. Clin Transplant 2012: 26: E536.
40. Lebranchu Y, Baan C, Biancone L et al. Pretransplant identification of acute rejection risk following kidney transplantation. Transpl Int 2014: 27: 129.
41. Sawitzki B, Pascher A, Babel N, Reinke P, Volk HD. Can we use biomarkers and functional assays to implement personalized therapies in transplantation? Transplantation 2009: 87: 1595.
42. Nickel P, Presber F, Bold G et al. Enzyme-linked immunosorbent spot assay for donor-reactive interferon-gamma-producing cells identifies T-cell presensitization and correlates with graft function at 6 and 12 months in renal-transplant recipients. Transplantation 2004: 78: 1640.
43. Ford ML, Kirk AD, Larsen CP. Donor-reactive T-cell stimulation history and precursor frequency: barriers to tolerance induction. Transplantation 2009: 87: S69.
44. Brehm MA, Markees TG, Daniels KA, Greiner DL, Rossini AA, Welsh RM. Direct visualization of cross-reactive effector and memory allo-specific CD8 T cells generated in response to viral infections. J Immunol 2003: 170: 4077.
45. Cortesini R, LeMaoult J, Ciubotariu R, Cortesini NS. CD8+ CD28- T suppressor cells and the induction of antigen-specific, antigen-presenting cell-mediated suppression of Th reactivity. Immunol Rev 2001: 182: 201.
46. Colovai AI, Mirza M, Vlad G et al. Regulatory CD8+ CD28- T cells in heart transplant recipients. Hum Immunol 2003: 64: 31.
47. Baeten D, Louis S, Braud C et al. Phenotypically and functionally distinct CD8+ lymphocyte populations in long-term drug-free tolerance and chronic rejection in human kidney graft recipients. J Am Soc Nephrol 2006: 17: 294.
48. Betjes MG, Meijers RW, de Wit EA, Weimar W, Litjens NH. Terminally differentiated CD8+ Temra cells are associated with the risk for acute kidney allograft rejection. Transplantation 2012: 94: 63.
49. Takahashi T, Dejbakhsh-Jones S, Strober S. Expression of CD161 (NKR-P1A) defines subsets of human CD4 and CD8 T cells with different functional activities. J Immunol 2006: 176: 211.